NM-2-AI

N-methyl-2-aminoindane

Sources

1 strong · 16 moderate · 4 weak

Studies and references cited across this article, graded by evidence strength.

Values approved

135/136 (99%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	5 mg	5 mg	low
Low	50–100 mg	50–100 mg	low
Common	100–150 mg	100–150 mg	low
Strong	150–200 mg	150–200 mg	low
Heavy	200+ mg	200+ mg	low
Editorial	All dose values from existing DB / community consensus (PsychonautWiki confirmed matching data). No controlled human dosing study exists for NM-2-AI. The threshold value (5 mg) has an unusually large gap to light range (50 mg) and may be inaccurate — flagged for editorial review. Dose values are safety-critical and entirely unvalidated by clinical data.
	ReasoningReasoning All dose values from existing DB / community consensus (PsychonautWiki confirmed matching data). No controlled human dosing study exists for NM-2-AI. The threshold value (5 mg) has an unusually large gap to light range (50 mg) and may be inaccurate — flagged for editorial review. Dose values are safety-critical and entirely unvalidated by clinical data. Evidence basis: community_consensus_large

Duration

oral

Field	Published	AI Proposed	Confidence
Onsettrace	30–60 minutes	30–60 minutes	low
Editorial	Onset 30–60 minutes from existing DB / community consensus (PsychonautWiki). No controlled human PK data. Community reports indicate onset at 30–60 minutes, suggesting rapid absorption and N-demethylation.
	ReasoningReasoning Onset 30–60 minutes from existing DB / community consensus (PsychonautWiki). No controlled human PK data. Community reports indicate onset at 30–60 minutes, suggesting rapid absorption and N-demethylation. Evidence basis: community_consensus_large
Come uptrace	15–30 minutes	15–30 minutes	low
Editorial	Come-up phase proposed by Phase 1 at 15–30 minutes based on stimulant class norms and total duration constraint (2–4 hours). No published data for this phase.
	ReasoningReasoning Come-up phase proposed by Phase 1 at 15–30 minutes based on stimulant class norms and total duration constraint (2–4 hours). No published data for this phase. Evidence basis: structural_analogy
Peaktrace	45–90 minutes	45–90 minutes	low
Editorial	Peak duration proposed by Phase 1 at 45–90 minutes based on total duration (2–4 hours) and stimulant class temporal profile. No published data for this phase.
	ReasoningReasoning Peak duration proposed by Phase 1 at 45–90 minutes based on total duration (2–4 hours) and stimulant class temporal profile. No published data for this phase. Evidence basis: structural_analogy
Offsettrace	30–60 minutes	30–60 minutes	low
Editorial	Offset proposed by Phase 1 at 30–60 minutes based on total duration and stimulant class rapid offset pattern. Community reports describe rapid decline, consistent with short-acting stimulant profile.
	ReasoningReasoning Offset proposed by Phase 1 at 30–60 minutes based on total duration and stimulant class rapid offset pattern. Community reports describe rapid decline, consistent with short-acting stimulant profile. Evidence basis: structural_analogy
Totaltrace	2–4 hours	2–4 hours	low
Editorial	Total duration 2–4 hours from existing DB / community consensus (PsychonautWiki). This represents subjective experience duration, not pharmacological half-life. No controlled human data.
	ReasoningReasoning Total duration 2–4 hours from existing DB / community consensus (PsychonautWiki). This represents subjective experience duration, not pharmacological half-life. No controlled human data. Evidence basis: community_consensus_large
After effectstrace	2–6 hours	2–6 hours	low
Editorial	Aftereffects proposed by Phase 1 at 2–6 hours based on stimulant comedown/fatigue pattern. Post-acute depression, irritability, cognitive fatigue, and insomnia are class-typical for monoamine releasing agents.
	ReasoningReasoning Aftereffects proposed by Phase 1 at 2–6 hours based on stimulant comedown/fatigue pattern. Post-acute depression, irritability, cognitive fatigue, and insomnia are class-typical for monoamine releasing agents. Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	moderate	moderate	low
Chronic	low	low	low
Organs Affected	cardiovascular, pulmonary, hepatic	cardiovascular, pulmonary, hepatic	low
Editorial	Acute toxicity rated moderate per work-notes based on in silico predictions (Jurowski & Frydrych 2026) and one polydrug fatality. Chronic toxicity proposed as low (discounted from work-notes 'no data' per evidence discount rule — MDAI hepatotoxicity in HepG2 is the closest analog data but may not translate due to different ring substitution). All values are computational predictions or structural analogy to MDAI, not experimental measurements for NM-2-AI.
	ReasoningReasoning Acute toxicity rated moderate per work-notes based on in silico predictions (Jurowski & Frydrych 2026) and one polydrug fatality. Chronic toxicity proposed as low (discounted from work-notes 'no data' per evidence discount rule — MDAI hepatotoxicity in HepG2 is the closest analog data but may not translate due to different ring substitution). All values are computational predictions or structural analogy to MDAI, not experimental measurements for NM-2-AI. Evidence basis: structural_analogy

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	low	low	low
Psychological	moderate	moderate	low
Compulsive Redosing	high	high	low
Dose Escalation	moderate	moderate	low
Editorial	Work-notes specify physical dependence low-to-moderate, psychological moderate, compulsive redosing moderate-to-high. Proposed physical as 'low' and compulsive redosing as 'high' to capture the short-duration redosing driver emphasized in both work-notes and article prose. MDAI conditioned place preference in mice (Gatch et al. 2016) confirms abuse potential in the aminoindane class. No published NM-2-AI dependence studies exist — all values from community consensus.
	ReasoningReasoning Work-notes specify physical dependence low-to-moderate, psychological moderate, compulsive redosing moderate-to-high. Proposed physical as 'low' and compulsive redosing as 'high' to capture the short-duration redosing driver emphasized in both work-notes and article prose. MDAI conditioned place preference in mice (Gatch et al. 2016) confirms abuse potential in the aminoindane class. No published NM-2-AI dependence studies exist — all values from community consensus. Evidence basis: community_consensus_large

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	mild	mild	low
Symptoms	fatigue, depression, hypersomnia, irritability, cognitive fog, increased appetite	fatigue, depression, hypersomnia, irritability, cognitive fog, increased appetite	low
Fatal	No	No	low
Medical Supervision	Not required	Not required	low
Editorial	No published withdrawal data for NM-2-AI. Withdrawal existence marked true based on class-level stimulant withdrawal profile (fatigue, depression, hypersomnia). Severity rated mild — stimulant withdrawal is typically not medically dangerous. All parameters inferred from stimulant class norms.
	ReasoningReasoning No published withdrawal data for NM-2-AI. Withdrawal existence marked true based on class-level stimulant withdrawal profile (fatigue, depression, hypersomnia). Severity rated mild — stimulant withdrawal is typically not medically dangerous. All parameters inferred from stimulant class norms. Evidence basis: community_consensus_large

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	moderate	moderate	low
Half-life	5 days	5 days	low
Full Reset	10 days	10 days	low
Cross-tolerances	dopaminergic stimulants, other monoamine releasing agents	dopaminergic stimulants, other monoamine releasing agents	low
Editorial	Tolerance half-life (~5 days) and full reset (~1.5 weeks / 10 days) from existing DB / community consensus. Buildup rated moderate per work-notes. Cross-tolerances expanded from seed data 'dopamine, stimulant' to explicit 'dopaminergic stimulants, other monoamine releasing agents'. Mechanism inferred from stimulant class — no published NM-2-AI tolerance data.
	ReasoningReasoning Tolerance half-life (~5 days) and full reset (~1.5 weeks / 10 days) from existing DB / community consensus. Buildup rated moderate per work-notes. Cross-tolerances expanded from seed data 'dopamine, stimulant' to explicit 'dopaminergic stimulants, other monoamine releasing agents'. Mechanism inferred from stimulant class — no published NM-2-AI tolerance data. Evidence basis: community_consensus_large

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
other Concurrent MAOI usetrace	absolute	absolute	medium
Editorial	Class-level absolute contraindication for all monoamine releasing agents. No NM-2-AI-specific case data, but mechanism is well-established pharmacologically.
	ReasoningReasoning Class-level absolute contraindication for all monoamine releasing agents. No NM-2-AI-specific case data, but mechanism is well-established pharmacologically.
cardiovascular Uncontrolled hypertensiontrace	absolute	absolute	medium
Editorial	Class-level contraindication for all NET-releasing stimulants. NM-2-AI's inferred NET-dominant pharmacology makes this particularly relevant. No substance-specific data.
	ReasoningReasoning Class-level contraindication for all NET-releasing stimulants. NM-2-AI's inferred NET-dominant pharmacology makes this particularly relevant. No substance-specific data.
cardiovascular Severe cardiovascular diseasetrace	absolute	absolute	low
Editorial	In silico cardiovascular toxicity prediction (82%) combined with class-level sympathomimetic mechanism. The 82% figure is a computational model output, not experimental measurement.
	ReasoningReasoning In silico cardiovascular toxicity prediction (82%) combined with class-level sympathomimetic mechanism. The 82% figure is a computational model output, not experimental measurement.
neurological Seizure disorderstrace	relative	relative	low
Editorial	Class-level relative contraindication for all stimulant/monoamine releasing agents. No NM-2-AI-specific seizure case reports exist.
	ReasoningReasoning Class-level relative contraindication for all stimulant/monoamine releasing agents. No NM-2-AI-specific seizure case reports exist.
hepatic Hepatic impairmenttrace	relative	relative	low
Editorial	Class-level relative contraindication based on hepatic metabolism pathway and MDAI hepatotoxicity data. MDAI cytotoxicity may not translate to NM-2-AI due to different ring substitution.
	ReasoningReasoning Class-level relative contraindication based on hepatic metabolism pathway and MDAI hepatotoxicity data. MDAI cytotoxicity may not translate to NM-2-AI due to different ring substitution.
psychiatric Bipolar disordertrace	relative	relative	low
Editorial	Class-level relative contraindication for stimulant/monoamine releasing agents. No NM-2-AI-specific psychiatric case data exist.
	ReasoningReasoning Class-level relative contraindication for stimulant/monoamine releasing agents. No NM-2-AI-specific psychiatric case data exist.
psychiatric Psychosis spectrum disorderstrace	relative	relative	low
Editorial	Class-level relative contraindication for dopamine-releasing stimulants. No NM-2-AI-specific psychosis case reports, but stimulant psychosis is a well-established class risk.
	ReasoningReasoning Class-level relative contraindication for dopamine-releasing stimulants. No NM-2-AI-specific psychosis case reports, but stimulant psychosis is a well-established class risk.
pregnancy breastfeeding Pregnancytrace	absolute	absolute	medium
Editorial	Class-level absolute contraindication for all sympathomimetic vasoconstrictors in pregnancy. No substance-specific reproductive data.
	ReasoningReasoning Class-level absolute contraindication for all sympathomimetic vasoconstrictors in pregnancy. No substance-specific reproductive data.

Timeline Phases

oral

Field	Published	AI Proposed	Confidence
Onsettrace	1800–3600 sec(i=0.05)	1800–3600 sec(i=0.05)	low
Editorial	Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences.
	ReasoningReasoning Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences. Evidence basis: community_consensus_large
Come uptrace	900–1800 sec(i=0.40)	900–1800 sec(i=0.40)	low
Editorial	Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences.
	ReasoningReasoning Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences. Evidence basis: community_consensus_large
Peaktrace	2700–5400 sec(i=1.00)	2700–5400 sec(i=1.00)	low
Editorial	Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences.
	ReasoningReasoning Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences. Evidence basis: community_consensus_large
Resolutiontrace	1800–3600 sec(i=0.30)	1800–3600 sec(i=0.30)	low
Editorial	Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences.
	ReasoningReasoning Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences. Evidence basis: community_consensus_large
Afterglowtrace	7200–21600 sec(i=0.10)	7200–21600 sec(i=0.10)	low
Editorial	Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences.
	ReasoningReasoning Onset (30–60 min) and total (2–4 h) from existing DB / community consensus. Come-up (15–30 min), peak (45–90 min), offset (30–60 min), and aftereffects (2–6 h) proposed by Phase 1 based on stimulant class norms and total duration constraints. No controlled human pharmacokinetic data exist for NM-2-AI. All phase durations are community estimates or class-level inferences. Evidence basis: community_consensus_large

Dose Tier Summaries

lighttrace

low

At 50–100 mg oral, NM-2-AI produces mild stimulation and increased wakefulness. Cognitive effects include subtle thought acceleration and a slight sharpening of focus, though below the threshold for productive enhancement. A faint mood lift may be perceptible, but entactogenic warmth is absent at this range. Physical effects are modest: mild appetite suppression, slight increase in heart rate awareness, and a subtle energizing body feeling. Bruxism and excessive sweating are unlikely at this level. Duration remains short (2–4 hours total), and aftereffects are mild. Functional impairment is minimal, though sleep may be delayed if dosed in the evening.

Editorial

Light range (50–100 mg) from existing DB / community consensus. Effects described by analogy with stimulant class norms at sub-common doses. No controlled human data.

Reasoning

Light range (50–100 mg) from existing DB / community consensus. Effects described by analogy with stimulant class norms at sub-common doses. No controlled human data.

Evidence basis: community_consensus_large

thresholdtrace

low

At approximately 5 mg, NM-2-AI produces sub-perceptual stimulant awareness. Effects at this level are minimal — a possible faint increase in alertness or slight physiological activation, but no meaningful psychoactive response. Most users report no discernible subjective change. This dose range serves primarily for allergy testing and individual sensitivity assessment. No cognitive enhancement, mood elevation, or physical stimulation is expected. The gap between threshold (5 mg) and light (50 mg) is unusually large and may reflect inaccurate threshold data rather than a genuine pharmacological plateau. Conservative titration through this range is advisable.

Editorial

Threshold value (5 mg) from existing DB / community consensus (PsychonautWiki). No controlled dosing studies exist. The unusually large gap between threshold and light dose was flagged by Phase 1 as potentially inaccurate.

Reasoning

Evidence basis: community_consensus_large

commontrace

low

At 100–150 mg oral, NM-2-AI delivers its core stimulant profile: pronounced wakefulness, physical stimulation, and noticeable thought acceleration. Appetite suppression becomes reliable. Mild euphoria emerges, though attenuated compared to dopamine-dominant stimulants. Some users report faint prosocial warmth at the upper end of this range, but empathogenic depth remains limited. Physical effects include increased heart rate, mild bruxism, excessive sweating, and dehydration sensation. Cardiovascular activation is perceptible. Nausea may occur during onset but typically resolves as stimulation builds. The short duration (2–4 hours) creates pressure toward compulsive redosing. Post-acute cognitive fatigue, low mood, and irritability are common as effects wane.

Editorial

Common range (100–150 mg) from existing DB / community consensus. Effects profile assembled from seed effect data, community reports, and class-level stimulant/entactogen norms. No controlled human study.

Reasoning

Evidence basis: community_consensus_large

strongtrace

low

At 150–200 mg oral, stimulation intensifies markedly. Euphoria becomes more pronounced, alongside strong thought acceleration, heightened motivation, and analysis enhancement. The compulsive redosing urge is prominent at this level — the rapid offset strongly drives re-administration. Cardiovascular effects escalate: abnormal heartbeat perception, elevated blood pressure, pronounced bruxism, and excessive sweating are expected. Restlessness and anxiety may emerge, particularly in stimulant-sensitive individuals or anxiogenic settings. Temperature dysregulation becomes a consideration. Post-acute depression, irritability, and cognitive fatigue are more likely and more intense than at common doses. Sleep disruption extends well beyond the subjective duration. Risk-benefit ratio narrows significantly at this tier.

Editorial

Strong range (150–200 mg) from existing DB / community consensus. Adverse effect escalation inferred from stimulant class dose-response and community reports. In silico cardiovascular toxicity prediction (82%) supports caution.

Reasoning

Evidence basis: community_consensus_large

heavytrace

low

Doses exceeding 200 mg enter territory with no established safety ceiling. All stimulant adverse effects are amplified — severe cardiovascular strain, intense anxiety and agitation, pronounced bruxism, and excessive sweating. At these levels, the risk of stimulant-induced paranoia or psychotic features increases, particularly with repeated dosing within a session. Physically, sympathomimetic overload presents the primary danger: hypertensive emergency, cardiac arrhythmia, and hyperthermia are all plausible at extreme doses, though no human dose-toxicity relationship has been established. No controlled data exist for this range. One polydrug fatality has been documented (NM-2-AI 95.4 ng/mL alongside MAB-CHMINACA). The exact toxic dose in humans remains unknown.

Editorial

Heavy threshold (200+ mg) from existing DB / community consensus. Adverse effect descriptions from class-level stimulant toxicology and the documented polydrug fatality (DEA 2021). No controlled data at any dose level.

Reasoning

Evidence basis: community_consensus_large

History

current version

published Oct 2, 2026system—

versions

2 total · since previous: +1 / −1 citations

+ Aminoindanes (UNODC Substance Group Details) (2015)

− Details for Aminoindanes (2017)

publication ledger

publish Oct 2, 2026 · by agent-psx

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

1 strong · 16 moderate · 4 weak

[1]
moderate
Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives.
Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME · 2014 · Biochemical Pharmacology
doi.org/10.1016/j.bcp.2014.01.024 pubmed 24486525no claims checked
[2]
moderate
2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and alpha2-adrenergic receptors
Halberstadt A, Brandt S, Walther D, Baumann M · 2019 · Psychopharmacology
doi.org/10.1007/s00213-019-05207-1no claims checked
[3]
strong
Synthetic Aminoindanes: A Summary of Existing Knowledge.
Pinterova N, Horsley RR, Palenicek T · 2017 · Frontiers in Psychiatry
doi.org/10.3389/fpsyt.2017.00236 pubmed 29204127no claims checked
[4]
weak
DEA Alert Regarding N-Methyl-2-Aminoindane (NM-2-AI)
US Drug Enforcement Administration · 2021
linkno claims checked
[5]
weak
Aminoindanes (UNODC Substance Group Details)
UNODC · 2015
linkno claims checked
[6]
moderate
Behavioral and Pharmacokinetics Studies of N-Methyl-2-Aminoindane (NM2AI) in Mice: An Aminoindane Briefly Used in the Illicit Drug Market.
Tirri M, Corli G, Arfe R, Marchetti B, Bilel S, Bernardi T, Boccuto F, Odoardi S, Mestria S, Strano-Rossi S, Marti M · 2023 · International Journal of Molecular Sciences
doi.org/10.3390/ijms24031882 pubmed 36768197no claims checked
[7]
moderate
First toxicity profile of 2-aminoindane and N-Methyl-2-aminoindane using in silico multi-approach.
Jurowski K, Frydrych A · 2026 · Toxicology in Vitro
doi.org/10.1016/j.tiv.2025.106149 pubmed 41005718no claims checked
[8]
moderate
In vitro actions of NN-dimethyl-2-aminoindane and related compounds.
Little HJ, Rees JM · 1980 · Journal of Pharmacy and Pharmacology
pubmed 6110722no claims checked
[9]
moderate
(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of MDMA-like behavioral activity.
Oberlender R, Nichols DE · 1990 · Journal of Pharmacology and Experimental Therapeutics
pubmed 1979813no claims checked
[10]
moderate
Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic MDMA analogue.
Johnson MP, Huang XM, Nichols DE · 1991 · Pharmacology, Biochemistry, and Behavior
pubmed 1726189no claims checked
[11]
moderate
A snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015
Odoardi S, Romolo FS, Strano-Rossi S · 2016 · Forensic science international
doi.org/10.1016/j.forsciint.2016.01.037 pubmed 26874736no claims checked
[12]
weak
N-Methyl-2-Aminoindane (NM-2-AI) Substance Details
United Nations Office on Drugs and Crime (UNODC) · 2020
linkno claims checked
[13]
moderate
Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling
Liechti ME · 2015 · Swiss Medical Weekly
doi.org/10.4414/smw.2015.14043 pubmed 25588018no claims checked
[14]
moderate
The metabolic fate of two new psychoactive substances - 2-aminoindane and N-methyl-2-aminoindane - studied in vitro and in vivo to support drug testing.
Manier SK, Felske C, Eckstein N, Meyer MR · 2020 · Drug Testing and Analysis
doi.org/10.1002/dta.2699 pubmed 31667988no claims checked
[15]
moderate
Metabolism Study of N-Methyl 2-Aminoindane (NM2AI) and Determination of Metabolites in Biological Samples by LC-HRMS.
Mestria S, Odoardi S, Federici S, Bilel S, Tirri M, Marti M, Strano Rossi S · 2021 · Journal of Analytical Toxicology
doi.org/10.1093/jat/bkaa111 pubmed 32860694no claims checked
[16]
moderate
Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
Tarral A, Dostert P, Guillevic Y, et al. · 2003 · Journal of Clinical Pharmacology
pubmed 12953347no claims checked
[17]
moderate
Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.
Angerer V, Schmid Y, Franz F, Gnann H, Speer JM, Gnann A, Helmecke S, Buchwald A, Brandt SD, Passie T, Liechti ME, Auwärter V · 2024 · Drug Testing and Analysis
doi.org/10.1002/dta.3622 pubmed 38056906no claims checked
[18]
moderate
Cytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay.
Richter LHJ, Beck A, Flockerzi V, Maurer HH, Meyer MR · 2019 · Toxicology Letters
doi.org/10.1016/j.toxlet.2018.11.007 pubmed 30465810no claims checked
[19]
moderate
Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats.
Palenicek T, Lhotkova E, Zidkova M, Balikova M, Kuchař M, Himl M, Miksatkova P, Cegan M, Vales K, Tylš F, Horsley RR · 2016 · Progress in Neuro-Psychopharmacology & Biological Psychiatry
doi.org/10.1016/j.pnpbp.2016.04.004 pubmed 27083855no claims checked
[20]
moderate
Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents.
Gatch MB, Dolan SB, Forster MJ · 2016 · Behavioural Pharmacology
doi.org/10.1097/fbp.0000000000000237 pubmed 27028902no claims checked
[21]
weak
Death following consumption of MDAI and 5-EAPB
Deville M, Dubois N, Cieckiewicz E, De Tullio P, Lemaire E, Charlier C · 2019 · Forensic Science International
doi.org/10.1016/j.forsciint.2019.03.023 pubmed 30981086no claims checked

Claim Verification

No claim verification has run for this version.

Coverage & Gaps

effect links

107 links · 106 approved · 20 audited0/107 with evidence basis

interactions

3 approved pairs0/3 graded

NM-2-AI

Value Provenance

Dosing

oraltrace →

Duration

oral

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

oral

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

oraltrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace